News | Cardiac Imaging | September 13, 2017

Philips Showcases Integrated Vascular Solutions at VIVA 2017

Company will highlight patient-centric interventional peripheral vascular solutions for diagnosis, image-guided therapy and connected care

Philips Showcases Integrated Vascular Solutions at VIVA 2017

September 13, 2017 — Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from Sept. 11 – 14, 2017, applying advanced technologies and deep clinical insights to address peripheral vascular needs. With the addition of its recent acquisition, Spectranetics, Philips will for the first time highlight its expanded portfolio of interventional X-ray systems, advanced catheters for measurement and therapy, clinical informatics and services, including its Philips Azurion image-guided therapy platform, intravascular ultrasound (IVUS), Phoenix atherectomy system and Spectranetics' Stellarex drug-coated balloon.

More than 8 million people in the U.S. alone are affected by peripheral arterial disease (PAD) [1]. Many people do not experience symptoms and are not aware of even having the disease. In addition to having limited blood flow to the leg, patients are at increased risk for heart attack or stroke. Fortunately, PAD can be accessed and addressed through innovative solutions using minimally invasive procedures like atherectomy and cardiac imaging technology that may offer more accurate and reliable treatment options that can reduce recovery time for patients.

On Wednesday, Sept. 13, as part of the VIVA 17 Late-Breaking Clinical Trials program, Marianne Brodmann M.D., of the Medical University of Graz in Austria will present two-year data from the ILLUMENATE European randomized clinical trial (EU RCT) that evaluates how Spectranetics' Stellarex drug-coated balloon restores and maintains blood flow to arteries in patients with PAD. Stellarex received U.S. Food and Drug Administration (FDA) approval in July 2017. The ILLUMENATE EU RCT analyzes patency in the segment of diseased artery treated with Stellarex in over 300 patients from a challenging patient population.

The combination of Spectranetics' product range and Philips' portfolio of interventional imaging systems, devices, software and services offer innovative solutions for peripheral vascular therapy, according to the company. At this year's VIVA conference, Philips and Spectranetics will showcase technology including:

  • Stellarex, the only commercially available drug-coated balloon with two reported randomized controlled trials. It has demonstrated durability with consistently high patency rates in a wide range of patients, according to Philips;
  • Azurion is an image-guided therapy platform that enables clinicians to easily and confidently perform a range of routine and complex procedures, helping them to optimize interventional lab performance;
  • The Pioneer Plus catheter, a re-entry device with intravascular ultrasound (IVUS), a catheter-based imaging technology that allows physicians to visualize diseased vessels from inside the artery, to facilitate identification of true lumen location;
  • The Phoenix atherectomy system, which combines the benefits of existing atherectomy systems and delivers a hybrid [2] atherectomy option to help physicians tailor the treatment approach for each patient; and
  • SymphonySuite is Philips' comprehensive program that includes a robust set of tools to support efforts in opening, growing and maintaining office-based lab solutions.

For more information: www.usa.philips.com/healthcare

 

References

1. National Institutes of Health, Facts About Peripheral Arterial Disease (P.A.D.), NHLBI.NIH.gov, September 2017 
2. Directional cutting ability only available with Phoenix 2.4mm deflecting catheter

Related Content

Jackson Memorial Hospital Holds Ribbon-cutting for New Cardiac Catheterization Labs
News | Angiography | August 21, 2019
Jackson Memorial Hospital in Miami celebrated the opening of two newly renovated cardiac catheterization suites during...
Videos | CT Angiography (CTA) | August 07, 2019
This is a quick walk around of the new Siemens Somatom Go.top cardiovascular edition compact computed tomography (CT)
Videos | CT Angiography (CTA) | August 07, 2019
This is a quick walk around of the GE Healthcare Cardiographe dedicated cardiac CT system on display at the...
Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing
News | Cardiovascular Ultrasound | August 07, 2019
Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for...
Artificial Intelligence Improves Heart Attack Risk Assessment
News | CT Angiography (CTA) | August 06, 2019
When used with a common heart scan, machine learning, a type of artificial intelligence (AI), does better than...
An example of FFR-CT imaging from Beaumont Hospital in Royal Oak, Mich. The left image shows a 3D generated image of the coronary tree from a CT scan evaluated with computational fluid dynamics to determine the FFR numbers. It shows a severe restriction of the left main artery which requires a stent to revacularize. The image on the right is a comparison with the invasive angiogram from the cath lab prior to stenting.

An example of FFR-CT imaging from Beaumont Hospital in Royal Oak, Mich. The left image shows a 3D generated image of the coronary tree from a CT scan evaluated with computational fluid dynamics to determine the FFR numbers. It shows a severe restriction of the left main artery which requires a stent to revacularize. The image on the right is a comparison with the invasive angiogram from the cath lab prior to stenting. 

Feature | Cardiac Imaging | July 24, 2019 | Greg Freiherr
One of the big trends in cardiac computed tomography (CT) imaging has been the introduction of noninvasive...